EMPA-REG OUTCOME
Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes
Paciente / Población Intervención / Exposición Comparación Desenlace
In 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.
N
7020
Diseño
Double-blind RCT
Desenlace
CV death, MI or stroke
Relevancia
1
Resultado3-point MACE HR 0.86; CV death down 38 %; HF hospitalisation down 35 %.
Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128. 10.1056/NEJMoa1504720
Discusión y crítica
First cardiovascular-outcomes trial to show an SGLT2-inhibitor benefit — unexpectedly driven by heart failure and CV death, launching the SGLT2i era.